Akışa dön
85/100 Bearish 30.07.2026 · 13:47 Finrend AI ⏱ 1 dk 👁 3 TR

Teladoc Cuts Revenue Forecast on Weaker BetterHelp Demand, Shares Plunge

Teladoc Health has revised its 2024 revenue forecast downward due to shifting demand for its online therapy platform BetterHelp, leading to a sharp decline in its stock price. The company cited weaker-than-expected customer demand, particularly in the BetterHelp segment, which negatively impacted overall revenue expectations. According to the new guidance, Teladoc's total revenue for 2024 will fall below the previously projected range. This revision reflects the challenges Teladoc faces as demand for online health services normalizes in the post-pandemic period. BetterHelp experienced significant growth during the pandemic but has recently seen a decline in demand. Analysts suggest that this demand shift could pressure Teladoc's long-term growth strategy. While the company is implementing cost control and operational efficiency measures to navigate this period, the lowered revenue forecast has shaken investor confidence. Teladoc shares lost over 20% in trading following the announcement. The company has outlined plans to restructure BetterHelp and focus on new growth areas, though the market remains cautious about the short-term impact of these steps. This is not investment advice.

📊 GOOGL — Piyasa Yorumu

■ neutral · 30%

Although GOOGL shares rose 2.3%, the RSI remains neutral at 51 and the MACD is below the signal line. The price is trading just below the 20-day SMA (334.40), which could create short-term resistance. Teladoc's revenue forecast cut and sharp decline in its stock may be interpreted as a sign of general weakness in the technology and healthcare sectors. However, since GOOGL's direct exposure to this news is limited, the impact may be contained. With technical indicators providing no clear direction, a sideways trend is expected in the short term.

RSI 14
51.3
MACD
0.67
24h Δ
2.30%
Canlı Grafikler

🔗 İlgili haberler

🧬 Buna benzer

AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.